세계의 주사용 인간 인터루킨 2 시장 보고서(2025년)

Injection Human Interleukin 2 Global Market Report 2025

US $ 4,490 ￦ 6,222,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,993,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,765,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

주사용 인간 인터루킨 2 시장 규모는 향후 몇 년 동안 급속한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 암 유병률 증가, 면역요법 치료에 대한 수요 증가, 맞춤형 의학의 확대, 정부 및 민간 부문에서의 암 연구에 대한 자금 지원 확대, 면역요법의 이점에 대한 인식 향상과 연관될 수 있습니다. 이 기간 동안의 주요 동향으로는 생명 공학 및 유전 공학의 발전, 복합 요법의 개발, 혁신적인 의약품 전달 시스템, 의약품의 효능 및 안전성 개선, 차세대 IL-2 요법의 개발 등이 있습니다.

맞춤형 의학의 채택이 증가함에 따라 주사용 인간 인터루킨 2 시장의 확장이 촉진될 것으로 예상됩니다. 개인 맞춤형 의학은 개인의 유전적 프로필, 생활 방식 및 환경에 따라 치료 및 예방 계획을 맞춤화합니다. 맞춤형 의학에 대한 수요 증가는 유전자 검사 기술의 발전에 힘입어 더 정확한 진단과 환자별 맞춤형 치료가 가능해졌기 때문입니다. 이는 치료 결과 개선과 부작용 감소로 이어집니다. 이로 인해 맞춤형 면역요법 프로토콜에서 환자의 독특한 면역 프로파일에 따라 IL-2를 투여하여 치료 효과를 최적화하고 부작용을 줄이는 데 주사용 인간 인터루킨 2의 사용이 증가하고 있습니다. 예를 들어, 2024년 2월, 미국에 본사를 둔 비영리 단체인 Personalized Medicine Coalition은 FDA가 2023년에 희귀 질환 환자를 위한 16개의 새로운 개인 맞춤형 의약품을 승인했다고 밝혔습니다. 이는 2022년의 6개에서 증가한 수치입니다. 그 결과, 개인 맞춤형 의학에 대한 관심이 높아짐에 따라 주사용 인간 인터루킨 2의 시장 성장이 촉진될 것으로 예상됩니다.

주사용 인간 인터루킨 2 시장 주요 기업들은 장기 치료 옵션 개발에 초점을 맞춰 저용량 인터루킨 2 기술 혁신에 주목하고 있습니다. 저용량 인터루킨 2는 조절 T 세포를 특정적으로 자극해 면역 관용을 강화하고 염증을 줄이며 부작용을 최소화하기 위해 소량의 IL-2를 투여하는 방식입니다. 예를 들어, 2024년 10월 미국 바이오테크 기업 코야 테라퓨틱스(Coya Therapeutics Inc.)는 알츠하이머 병(AD) 환자를 대상으로 피하 투여 저용량 인터루킨 2(LD IL-2)의 효과를 조사한 이중 맹검 연구 결과를 발표했습니다. 이 연구는 주요 및 부차적 평가 지표를 모두 충족했으며, T 효과 림프구에는 영향을 주지 않으면서 조절 T 세포(Tregs)를 증가시켰습니다. 탐색적 데이터는 4주마다 저용량 IL-2를 투여했을 때 인지 기능이 안정화되고 뇌척수액(CSF) 내 용해성 AB42 수치가 개선되며 CSF 신경필라멘트 경쇄(NfL)가 안정화되었다고 나타났습니다. 이러한 결과는 신경퇴행성 질환, 특히 알츠하이머 병 치료를 위한 Treg 조절에 대한 신뢰를 강화합니다. COYA 301은 피하 투여를 통해 염증을 조절함으로써 Treg 기능을 향상시키는 것을 목표로 하는 저용량 IL-2의 임상 시험용 약물입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 주사용 인간 인터루킨 2 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 주사용 인간 인터루킨 2 시장 : 성장률 분석
• 세계의 주사용 인간 인터루킨 2 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 주사용 인간 인터루킨 2 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 주사용 인간 인터루킨 2 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 주사용 인간 인터루킨 2 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 재조합 인간 인터루킨 2
• 천연 인간 인터루킨 2
• 세계의 주사용 인간 인터루킨 2 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 피하 주사
• 정맥 주사
• 근육내 주사
• 세계의 주사용 인간 인터루킨 2 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 직접 판매
• 약국
• 온라인 판매
• 세계의 주사용 인간 인터루킨 2 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 종양학
• 면역요법
• 자가면역질환
• 감염증
• 세계의 주사용 인간 인터루킨 2 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 클리닉
• 연구기관
• 기타 최종 사용자
• 세계의 주사용 인간 인터루킨 2 시장 : 재조합 인간 인터루킨 2 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 대장균 유래 인터루킨 2
• 효모 유래 인터루킨 2
• 포유류 세포 유래 인터루킨 2
• 세계의 주사용 인간 인터루킨 2 시장 : 천연 인간 인터루킨 2 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 혈장 유래 인터루킨 2
• 말초 혈액 단핵 세포 유래 인터루킨 2

제7장 지역별, 국가별 분석

• 세계의 주사용 인간 인터루킨 2 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 주사용 인간 인터루킨 2 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 주사용 인간 인터루킨 2 시장 : 경쟁 구도
• 주사용 인간 인터루킨 2 시장 : 기업 프로파일
  • F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Becton Dickinson and Company(BD) : 개요, 제품 및 서비스, 전략 및 재무 분석
  • BioNTech SE : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Corning Incorporated : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Bio-Rad Laboratories Inc.
• StemCell Technologies Canada Inc.
• Clinigen Group
• Iovance Biotherapeutics Inc.
• CUSABIO Technology LLC
• Elabscience Biotechnology Inc.
• Enzo Biochem Inc.
• InvivoGen
• Synthekine Inc.
• BPS Bioscience Inc.
• Xilio Therapeutics Inc.
• Qkine Ltd.
• MinneBio LLC
• Akron Biotechnology LLC
• Shandong Quangang Pharmaceutical Co. Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 주사용 인간 인터루킨 2 시장(2029년) : 새로운 기회를 제공하는 국가
• 주사용 인간 인터루킨 2 시장(2029년) : 새로운 기회를 제공하는 부문
• 주사용 인간 인터루킨 2 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Injection human interleukin 2 is a biologic drug primarily used in immunotherapy to stimulate the growth and activity of immune cells, such as T-cells and natural killer (NK) cells. It is a recombinant form of the naturally occurring cytokine interleukin-2, which plays a crucial role in regulating immune responses. By boosting the body's immune defenses, IL-2 injection helps to recognize and target cancer cells more effectively.

The primary product types of injection human interleukin 2 are recombinant human interleukin 2 and natural human interleukin 2. Recombinant human interleukin 2 is a synthetic version produced through recombinant DNA technology. It can be administered via subcutaneous, intravenous, or intramuscular injection and is distributed through direct sales, pharmacies, and online platforms. This drug is primarily used in oncology, immunotherapy, and for treating autoimmune diseases by various end-users, including hospitals, clinics, research institutes, and more.

The injection human interleukin 2 market research report is one of a series of new reports from The Business Research Company that provides injection human interleukin 2 market statistics, including injection human interleukin 2 industry global market size, regional shares, competitors with an injection human interleukin 2 market share, detailed injection human interleukin 2 market segments, market trends and opportunities, and any further data you may need to thrive in the injection human interleukin 2 industry. This injection human interleukin 2 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The injection human interleukin 2 market size has grown rapidly in recent years. It will grow from $1.10 billion in 2024 to $1.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be credited to advancements in healthcare infrastructure, a higher utilization of IL-2 for autoimmune diseases, a rising number of clinical trials, an expanding pipeline of cancer immunotherapy drugs, a growing global population, and an aging demographic.

The injection human interleukin 2 market size is expected to see rapid growth in the next few years. It will grow to $1.82 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth projected for the forecast period can be linked to the rising prevalence of cancer, increased demand for immunotherapy treatments, the expansion of personalized medicine, greater funding from both government and private sectors for cancer research, and growing awareness of the benefits of immunotherapy. Key trends during this period include advancements in biotechnology and genetic engineering, the development of combination therapies, innovative drug delivery systems, improvements in drug efficacy and safety, and the development of next-generation IL-2 therapies.

The growing adoption of personalized medicine is expected to drive the expansion of the injection human interleukin 2 market. Personalized medicine customizes treatment and prevention plans based on an individual's genetic profile, lifestyle, and environment. The rising demand for personalized medicine is fueled by advances in genetic testing, which allow for more accurate diagnoses and targeted therapies that are tailored to each patient's specific needs, resulting in better outcomes and fewer side effects. This increased demand for personalized treatments enhances the use of Injection Human Interleukin 2 in customized immunotherapy regimens, where IL-2 is administered based on the patient's unique immune profile to optimize therapeutic efficacy and reduce adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the FDA approved 16 novel personalized medicines for patients with rare diseases in 2023, up from six in 2022. As a result, the growing emphasis on personalized medicine is expected to drive the market growth of injection human interleukin 2.

Innovations in low-dose interleukin-2 are gaining attention from key players in the injection human interleukin-2 market, with a focus on developing long-term treatment options. Low-dose interleukin-2 involves administering small amounts of IL-2 to specifically stimulate regulatory T cells, boosting immune tolerance while reducing inflammation and minimizing side effects. For example, in October 2024, Coya Therapeutics Inc., a U.S.-based biotech company, shared results from a double-blind study investigating the effects of subcutaneous low-dose interleukin-2 (LD IL-2) in Alzheimer's disease (AD). The study successfully met its primary and secondary endpoints, enhancing regulatory T cells (Tregs) without impacting T effector lymphocytes. Exploratory data revealed that administering low-dose IL-2 every four weeks stabilized cognition, improved cerebrospinal fluid (CSF) soluble AB42 levels, and stabilized CSF Neurofilament Light Chain (NfL). These results bolster confidence in Treg modulation for treating neurodegenerative diseases, particularly Alzheimer's. COYA 301, an investigational low-dose IL-2, seeks to enhance Treg function through subcutaneous administration for modulating inflammation.

In September 2022, Roche Holding AG, a Switzerland-based pharmaceutical company, acquired Good Therapeutics Inc. for $250 million. This acquisition is part of Roche's strategy to enhance its immuno-oncology pipeline by developing innovative, conditionally active Interleukin-2 treatments that selectively activate immune responses within tumors, while minimizing systemic side effects. Good Therapeutics Inc. is a US-based biotech firm, focusing on creating conditionally active interleukin-2 therapies targeting programmed cell death protein 1 for cancer immunotherapy.

Major players in the injection human interleukin 2 market are F. Hoffmann-La Roche AG, Novartis AG, Becton Dickinson and Company (BD), BioNTech SE, Corning Incorporated, Bio-Rad Laboratories Inc., StemCell Technologies Canada Inc., Clinigen Group, Iovance Biotherapeutics Inc., CUSABIO Technology LLC, Elabscience Biotechnology Inc., Enzo Biochem Inc., InvivoGen, Synthekine Inc., BPS Bioscience Inc., Xilio Therapeutics Inc., Qkine Ltd., MinneBio LLC, Akron Biotechnology LLC, Shandong Quangang Pharmaceutical Co. Ltd., and Novoprotein Scientific Inc.

North America was the largest region in the injection human interleukin 2 market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in injection human interleukin 2 report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Injection Human Interleukin 2 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The injection human interleukin 2 market consists of sales of monoclonal antibodies, checkpoint inhibitors, cancer vaccines and immune modulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Injection Human Interleukin 2 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on injection human interleukin 2 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for injection human interleukin 2 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The injection human interleukin 2 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Recombinant Human Interleukin 2; Natural Human Interleukin 2
• 2) By Route Of Administration: Subcutaneous Injection; Intravenous Injection; Intramuscular Injection
• 3) By Distribution Channel: Direct Sales; Pharmacies; Online Sales
• 4) By Application: Oncology; Immunotherapy; Autoimmune Diseases
• 5) By End-User: Hospitals; Clinics; Research Institutes; Others End-Users
• Subsegments:
• 1) By Recombinant Human Interleukin 2: Escherichia Coli Derived Interleukin 2; Yeast Derived Interleukin 2; Mammalian Cell Derived Interleukin 2
• 2) By Natural Human Interleukin 2: Plasma Derived Interleukin 2; Peripheral Blood Mononuclear Cell Derived Interleukin 2
• Companies Mentioned: F. Hoffmann-La Roche AG; Novartis AG; Becton Dickinson and Company (BD); BioNTech SE; Corning Incorporated
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Injection Human Interleukin 2 Market Characteristics

3. Injection Human Interleukin 2 Market Trends And Strategies

4. Injection Human Interleukin 2 Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Injection Human Interleukin 2 Growth Analysis And Strategic Analysis Framework

• 5.1. Global Injection Human Interleukin 2 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Injection Human Interleukin 2 Market Growth Rate Analysis
• 5.4. Global Injection Human Interleukin 2 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Injection Human Interleukin 2 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Injection Human Interleukin 2 Total Addressable Market (TAM)

6. Injection Human Interleukin 2 Market Segmentation

• 6.1. Global Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Human Interleukin 2
• Natural Human Interleukin 2
• 6.2. Global Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous Injection
• Intravenous Injection
• Intramuscular Injection
• 6.3. Global Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Pharmacies
• Online Sales
• 6.4. Global Injection Human Interleukin 2 Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Immunotherapy
• Autoimmune Diseases
• Infectious Diseases
• 6.5. Global Injection Human Interleukin 2 Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Institutes
• Others End-Users
• 6.6. Global Injection Human Interleukin 2 Market, Sub-Segmentation Of Recombinant Human Interleukin 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Escherichia Coli Derived Interleukin 2
• Yeast Derived Interleukin 2
• Mammalian Cell Derived Interleukin 2
• 6.7. Global Injection Human Interleukin 2 Market, Sub-Segmentation Of Natural Human Interleukin 2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Plasma Derived Interleukin 2
• Peripheral Blood Mononuclear Cell Derived Interleukin 2

7. Injection Human Interleukin 2 Market Regional And Country Analysis

• 7.1. Global Injection Human Interleukin 2 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Injection Human Interleukin 2 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Injection Human Interleukin 2 Market

• 8.1. Asia-Pacific Injection Human Interleukin 2 Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Injection Human Interleukin 2 Market

• 9.1. China Injection Human Interleukin 2 Market Overview
• 9.2. China Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Injection Human Interleukin 2 Market

• 10.1. India Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Injection Human Interleukin 2 Market

• 11.1. Japan Injection Human Interleukin 2 Market Overview
• 11.2. Japan Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Injection Human Interleukin 2 Market

• 12.1. Australia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Injection Human Interleukin 2 Market

• 13.1. Indonesia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Injection Human Interleukin 2 Market

• 14.1. South Korea Injection Human Interleukin 2 Market Overview
• 14.2. South Korea Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Injection Human Interleukin 2 Market

• 15.1. Western Europe Injection Human Interleukin 2 Market Overview
• 15.2. Western Europe Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Injection Human Interleukin 2 Market

• 16.1. UK Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Injection Human Interleukin 2 Market

• 17.1. Germany Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Injection Human Interleukin 2 Market

• 18.1. France Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Injection Human Interleukin 2 Market

• 19.1. Italy Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Injection Human Interleukin 2 Market

• 20.1. Spain Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Injection Human Interleukin 2 Market

• 21.1. Eastern Europe Injection Human Interleukin 2 Market Overview
• 21.2. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Injection Human Interleukin 2 Market

• 22.1. Russia Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Injection Human Interleukin 2 Market

• 23.1. North America Injection Human Interleukin 2 Market Overview
• 23.2. North America Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Injection Human Interleukin 2 Market

• 24.1. USA Injection Human Interleukin 2 Market Overview
• 24.2. USA Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Injection Human Interleukin 2 Market

• 25.1. Canada Injection Human Interleukin 2 Market Overview
• 25.2. Canada Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Injection Human Interleukin 2 Market

• 26.1. South America Injection Human Interleukin 2 Market Overview
• 26.2. South America Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Injection Human Interleukin 2 Market

• 27.1. Brazil Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Injection Human Interleukin 2 Market

• 28.1. Middle East Injection Human Interleukin 2 Market Overview
• 28.2. Middle East Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Injection Human Interleukin 2 Market

• 29.1. Africa Injection Human Interleukin 2 Market Overview
• 29.2. Africa Injection Human Interleukin 2 Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Injection Human Interleukin 2 Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Injection Human Interleukin 2 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Injection Human Interleukin 2 Market Competitive Landscape And Company Profiles

• 30.1. Injection Human Interleukin 2 Market Competitive Landscape
• 30.2. Injection Human Interleukin 2 Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Becton Dickinson and Company (BD) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Corning Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. Injection Human Interleukin 2 Market Other Major And Innovative Companies

• 31.1. Bio-Rad Laboratories Inc.
• 31.2. StemCell Technologies Canada Inc.
• 31.3. Clinigen Group
• 31.4. Iovance Biotherapeutics Inc.
• 31.5. CUSABIO Technology LLC
• 31.6. Elabscience Biotechnology Inc.
• 31.7. Enzo Biochem Inc.
• 31.8. InvivoGen
• 31.9. Synthekine Inc.
• 31.10. BPS Bioscience Inc.
• 31.11. Xilio Therapeutics Inc.
• 31.12. Qkine Ltd.
• 31.13. MinneBio LLC
• 31.14. Akron Biotechnology LLC
• 31.15. Shandong Quangang Pharmaceutical Co. Ltd.

32. Global Injection Human Interleukin 2 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Injection Human Interleukin 2 Market

34. Recent Developments In The Injection Human Interleukin 2 Market

35. Injection Human Interleukin 2 Market High Potential Countries, Segments and Strategies

• 35.1 Injection Human Interleukin 2 Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Injection Human Interleukin 2 Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Injection Human Interleukin 2 Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer